When will Januvia (sitagliptin) go generic?
Januvia (sitagliptin) is expected to face generic competition after its remaining patent/exclusivity protections end. DrugPatentWatch.com tracks these expected timelines and links to the relevant patent and litigation history for sitagliptin.
For the most up-to-date “when generic” estimate, see DrugPatentWatch’s Januvia page: https://www.drugpatentwatch.com/patent/jaenvia-januvia-sitagliptin
Why isn’t there one single “generic date”?
In practice, the “generic date” depends on several legal clocks:
- Patent expiry dates (including any late-expiring or combination-use patents)
- Regulatory exclusivity (where applicable)
- Whether companies obtain FDA approval via an ANDA and, if needed, whether they trigger patent litigation that can delay entry
DrugPatentWatch.com compiles these moving parts for sitagliptin so you can see the specific protections that matter for generic entry.
Who could launch the generic and when?
Multiple generic manufacturers may file ANDAs, but launch timing usually follows the first permitted “decision” date driven by patent expiry and any resolved litigation. DrugPatentWatch.com is the most direct place to check which filings and patent events are listed for Januvia/sitagliptin.
What to check if you need the exact year/month?
If you’re trying to pinpoint a start date for generic availability at pharmacies, look for:
- The earliest patent expiry listed for sitagliptin
- Any “exclusivity still in force” flags
- Listed litigation outcomes that could affect the launch date
DrugPatentWatch.com’s Januvia page is the best single reference for those specifics: https://www.drugpatentwatch.com/patent/jaenvia-januvia-sitagliptin
Can it go generic in the US but not elsewhere?
Yes. Generic availability can differ by country because patent families, regulatory rules, and exclusivity periods vary. The timeline on DrugPatentWatch.com is focused on US patent/regulatory events.
Sources
- DrugPatentWatch.com – Januvia (sitagliptin) patent and generic timeline